Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[ash111]

kei you are right+ KIT-302 backup w/patent till 2029+ much better than Pfizer's Celebrex( that has suffered from major side effects and still has sales of 2-3B annually).
2 major events soon, 1. NDA Q4, 2. any day- The final and complete analyses, including the clinical study report,in October 2016. w/a former FDA officer and a former FDA Chemist, i'm calm. $25m cap Co. beats Pfizer,$200B Co.. i agree. sooner or later, PFE might knock the KTOV door. with improved celebrex Pfizer could easily pass $2.4B(2014 sales) even $3B sales IMO.

Today, there is no drug on the market that handles both things together - in pain as a result of osteoarthritis and high blood pressure. Therefore, the KIT-302 will be the only drug with indication for the treatment of pain while reducing the risk of heart attack and stroke may even brought a dying patient.

40% of docs "will prescribe over Celebrex",25 percent of doc's that won't RX Celebrex would RX KIT.
Third Party Payors say:
"People are going to use this... At the price range similar to branded Celebrex, it would enter the formulatory without a problem."- That's $7 per pill. Even at $0.25 a pill a day would be a revenue of $795m/yr (debt-free- most of rev will be transferred to Net Income) those numbers based on US market only. add also 7-10 yrs in EU and the rest of the World.

There is never 100% guarantee w/any stock and Biotech Weakness could drive PPS down as we seen past week but risk/reward ratio one of the most impressive I have seen.